Hybrid Amphotericin B derivatives with reduced toxicity

Martin D. Burke; Anuj Khandelwal; Jiabao Zhang; Anna SantaMaria

Hybrid Amphotericin B derivatives with reduced toxicity

Martin D. Burke (Inventor), Anuj Khandelwal (Inventor), Jiabao Zhang (Inventor), Anna SantaMaria (Inventor)

Research output: Patent

Abstract

Disclosed are derivatives of amphotericin B (AmB) characterized by improved clinical efficacy with reduced toxicity compared to AmB. Also disclosed are pharmaceutical compositions comprising the AmB derivatives, therapeutic methods of using the AmB derivatives and methods of making the AmB derivatives.

Original language	English (US)
U.S. patent number	11198705
Filing date	9/6/19
State	Published - Dec 14 2021

Library availability

Discover UIUC Full Text

Cite this

@misc{8e974788bc2b4ec2bf766e21fa3e9aac,

title = "Hybrid Amphotericin B derivatives with reduced toxicity",

abstract = "Disclosed are derivatives of amphotericin B (AmB) characterized by improved clinical efficacy with reduced toxicity compared to AmB. Also disclosed are pharmaceutical compositions comprising the AmB derivatives, therapeutic methods of using the AmB derivatives and methods of making the AmB derivatives.",

author = "Burke, {Martin D.} and Anuj Khandelwal and Jiabao Zhang and Anna SantaMaria",

note = "GOVERNMENT SUPPORT This invention was made with government support under Grant No. GM118185, awarded by the National Institutes of Health. The government has certain rights in the invention. ; 11198705",

year = "2021",

month = dec,

day = "14",

language = "English (US)",

type = "Patent",

}

TY - PAT

T1 - Hybrid Amphotericin B derivatives with reduced toxicity

AU - Burke, Martin D.

AU - Khandelwal, Anuj

AU - Zhang, Jiabao

AU - SantaMaria, Anna

N1 - GOVERNMENT SUPPORT This invention was made with government support under Grant No. GM118185, awarded by the National Institutes of Health. The government has certain rights in the invention.

PY - 2021/12/14

Y1 - 2021/12/14

N2 - Disclosed are derivatives of amphotericin B (AmB) characterized by improved clinical efficacy with reduced toxicity compared to AmB. Also disclosed are pharmaceutical compositions comprising the AmB derivatives, therapeutic methods of using the AmB derivatives and methods of making the AmB derivatives.

AB - Disclosed are derivatives of amphotericin B (AmB) characterized by improved clinical efficacy with reduced toxicity compared to AmB. Also disclosed are pharmaceutical compositions comprising the AmB derivatives, therapeutic methods of using the AmB derivatives and methods of making the AmB derivatives.

M3 - Patent

M1 - 11198705

Y2 - 2019/09/06

ER -

Hybrid Amphotericin B derivatives with reduced toxicity

Abstract

Library availability

Fingerprint

Cite this